RNF31 inhibitor - Flindr Therapeutics
Alternative Names: HOIP inhibitorLatest Information Update: 09 May 2024
At a glance
- Originator Flindr Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action RNF31 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 25 Apr 2024 Preclinical trials in Haematological malignancies in Netherlands (unspecified route) before April 2024
- 25 Apr 2024 Preclinical trials in Solid tumours in Netherlands (unspecified route) before April 2024
- 25 Apr 2024 Flindr Therapeutics plans to file IND in Solid tumors and Hematological malignancies